Back

Interference at Influenza Hemagglutinin Antigenic-Sites Determines Antibody Levels and Specificities after Repeat Vaccination

Anderson, C. S.; Topham, D. J.

2021-06-01 immunology
10.1101/2021.06.01.446556 bioRxiv
Show abstract

BackgroundIt is recommended that children receive a dose of the influenza vaccine at 6 months of age and a second dose the following season. In some years, the second dose will be the same vaccine formulation, in others years it with be re-formulated to include HA proteins derived from antigenically drifted or shifted circulating influenza strains. In addition, natural exposure to influenza can create permanent changes to the memory B cell repertoire and specificities. The effect that the specificity of pre-existing humoral immunity has on antibody levels and specificity after repeat vaccination is an ongoing research area. MethodsWe used a computational framework (ssMod.v1) to simulate scenarios that occurred during the 2009 influenza pandemic: children receiving a second dose who have previously exposed to the 2009 influenza HA antigen, children previously exposed to an HA antigen antigenically similar to the 2009 influenza HA antigen, and children previously exposed to an antigenically dissimilar strain. To assess the contribution of pre-existing immunity, two experimental permutations in the sMod.v1 were made: elimination of antibody-mediated antibody clearance of vaccine (HA) antigen by pre-existing antibodies and elimination of the ability of memory B cells to form germinal centers. In the simulation, 30 days after repeat vaccination antibody specificities were examined against 12 antigenically historical vaccine/HA variant influenza strains for each of the five canonical antigenic-sites and the subdominant, conserved, stalk antigenic-site. ResultsWe found that elimination of antibody-mediated antigen clearance significantly increased antibody levels while elimination of the ability of memory B cells to form germinal center reactions significantly decreased the total antibody levels, but this was dependent on the antigenic relationship between the original vaccine and repeat vaccine and the particular antigenic-site. Moreover, highly-cross-reactive antibody was highest when the antigenic distance between original vaccine HA antigen and repeat vaccine HA antigen was larger and antibody-mediated antigen clearance was eliminated.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
Vaccine
189 papers in training set
Top 0.1%
44.6%
2
BMC Medicine
163 papers in training set
Top 0.4%
6.8%
50% of probability mass above
3
Frontiers in Immunology
586 papers in training set
Top 1.0%
6.8%
4
Vaccines
196 papers in training set
Top 0.4%
5.2%
5
PLOS ONE
4510 papers in training set
Top 30%
5.2%
6
Human Vaccines & Immunotherapeutics
25 papers in training set
Top 0.3%
2.2%
7
PLOS Computational Biology
1633 papers in training set
Top 13%
2.2%
8
Scientific Reports
3102 papers in training set
Top 52%
2.0%
9
Vaccine: X
19 papers in training set
Top 0.1%
1.8%
10
JAMA Network Open
127 papers in training set
Top 2%
1.6%
11
American Journal of Preventive Medicine
11 papers in training set
Top 0.3%
1.4%
12
Journal of The Royal Society Interface
189 papers in training set
Top 3%
1.4%
13
Clinical Infectious Diseases
231 papers in training set
Top 4%
1.0%
14
Bioinformatics
1061 papers in training set
Top 8%
1.0%
15
F1000Research
79 papers in training set
Top 3%
1.0%
16
Influenza and Other Respiratory Viruses
44 papers in training set
Top 0.4%
0.8%
17
Open Forum Infectious Diseases
134 papers in training set
Top 2%
0.8%
18
The Journal of Infectious Diseases
182 papers in training set
Top 5%
0.8%
19
Immunology
29 papers in training set
Top 1%
0.7%
20
Frontiers in Public Health
140 papers in training set
Top 9%
0.7%
21
Computational and Structural Biotechnology Journal
216 papers in training set
Top 11%
0.5%
22
Frontiers in Physiology
93 papers in training set
Top 7%
0.5%
23
BMJ
49 papers in training set
Top 1%
0.5%
24
iScience
1063 papers in training set
Top 39%
0.5%
25
The Lancet Infectious Diseases
71 papers in training set
Top 4%
0.5%